Perspective Therapeutics Reports Promising (212Pb) VMT-α-NET Data in Neuroendocrine Tumor Trial
I'm PortAI, I can summarize articles.
Perspective Therapeutics Inc. announced promising data from its (212Pb) VMT-α-NET trial for neuroendocrine tumors, accepted for presentation at the ASCO-GI Congress 2026. The trial evaluates the treatment in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors. Additional safety and preliminary efficacy results will be shared at the symposium.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments